- Home
- CASY vs RPRX Comparison
CASY vs RPRX Comparison
Compare CASY & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASY
- RPRX
- Stock Information
- Founded
- CASY 1959
- RPRX 1996
- Country
- CASY United States
- RPRX United States
- Employees
- CASY N/A
- RPRX N/A
- Industry
- CASY Diversified Commercial Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- CASY Miscellaneous
- RPRX Health Care
- Exchange
- CASY Nasdaq
- RPRX Nasdaq
- Market Cap
- CASY 19.5B
- RPRX 15.6B
- IPO Year
- CASY N/A
- RPRX 2020
- Fundamental
- Price
- CASY $518.50
- RPRX $35.80
- Analyst Decision
- CASY Buy
- RPRX Strong Buy
- Analyst Count
- CASY 12
- RPRX 3
- Target Price
- CASY $467.33
- RPRX $45.33
- AVG Volume (30 Days)
- CASY 272.2K
- RPRX 3.8M
- Earning Date
- CASY 09-08-2025
- RPRX 11-05-2025
- Dividend Yield
- CASY 0.45%
- RPRX 2.46%
- EPS Growth
- CASY 9.01
- RPRX 54.86
- EPS
- CASY 14.64
- RPRX 2.32
- Revenue
- CASY $15,940,899,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- CASY $11.07
- RPRX $33.77
- Revenue Next Year
- CASY $5.73
- RPRX $4.62
- P/E Ratio
- CASY $35.62
- RPRX $15.40
- Revenue Growth
- CASY 7.25
- RPRX 3.02
- 52 Week Low
- CASY $362.42
- RPRX $24.05
- 52 Week High
- CASY $531.24
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- CASY 60.78
- RPRX 45.11
- Support Level
- CASY $505.00
- RPRX $35.48
- Resistance Level
- CASY $505.65
- RPRX $37.28
- Average True Range (ATR)
- CASY 8.63
- RPRX 0.79
- MACD
- CASY 1.10
- RPRX -0.03
- Stochastic Oscillator
- CASY 98.59
- RPRX 53.81
About CASY Casey's General Stores Inc.
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.